Opportunity Overview
The New Jersey Division of Purchase and Property (DPP) has an open RFP for T3165 – Naloxone, 4mg Nasal Spray, FDA-Approved, for the New Jersey Department of Human Services, Bid Solicitation 26DPP01283. NJSTART identifies the bid as open and permits electronic quotes.
Deadline and Contract Structure
The NJSTART header lists the bid opening as October 27, 2026 at 10:00 a.m., with the system displaying 10:00:59 a.m. The accessible official bid page does not state a time zone, so Atlas does not infer one. NJSTART shows a prospective contract term from February 7, 2027 through February 6, 2030.
Required Solicitation Materials
The current NJSTART attachment set includes the controlling Bid Solicitation, State-Supplied Price Sheet, State Standard Terms and Conditions, Standard Procurement Forms Packet, Specification Conformance Form, and Bidder Data Sheet. NJSTART states that bidders must price through the State-Supplied Price Sheet and identifies the item classification as miscellaneous drugs and pharmaceuticals.
Healthcare Relevance
This is a direct medication-procurement opportunity centered on FDA-approved naloxone nasal spray and therefore has strong opioid-overdose-response and medication-access relevance. Qualification, product conformance, distribution authority, pricing, packaging, supply, regulatory, insurance, registration, and other mandatory bidder requirements must be verified from the complete solicitation before any vendor is treated as eligible.
Atlas Analysis
Atlas Opportunity Score: 84/100. The procurement is highly relevant to medication access and overdose-response infrastructure, but it is a specialized pharmaceutical-supply contract rather than a grant.
N9+ Solution/Partner Fit: 0/100. Dr. Miltie Direct Vendor Fit: 0/100 at present. QC Healthcare Fit: 25/100, conditional. No current evidence establishes Dr. Miltie as an authorized naloxone manufacturer/distributor or establishes another Atlas entity as prime-qualified. A candidate path should be opened only after the full solicitation and the candidate’s actual pharmaceutical distribution authority and product-conformance evidence are verified.
Next Action
Potential bidders should retrieve the full current solicitation and price sheet, confirm authorized product sourcing and distribution, map every specification and compliance requirement, and complete the NJSTART electronic quote only after all mandatory gates are satisfied.
Verified source: New Jersey NJSTART Bid Solicitation 26DPP01283 / T3165.